Walker Luke Nathaniel 4

What Happened

• Walker Luke Nathaniel, a director of Context Therapeutics, was granted an award covering 45,000 shares (reported as a derivative acquisition) on June 24, 2026. The grant is reported at $0.00 per share (no cash paid at grant) and is listed as an award/option-type transaction rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed 2026-06-26 (timely filing).
• Transaction type/code: A (award/grant of a derivative security).
• Shares involved: 45,000 shares; reported price $0.00 (no cash exchanged at grant).
• Shares owned after transaction: not specified in the filing.
• Footnote (vesting): The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (one-year anniversary) or (ii) the issuer’s 2027 annual meeting of stockholders, subject to continued service with the company (Footnote F1).

Context

• This filing reflects a compensation grant to a director, a common practice to align management/directors with shareholder interests. It is not an immediate purchase or sale of stock; the award is subject to vesting and must become exercisable before any shares could be acquired or sold.
• Such grants are informative about director compensation but do not by themselves indicate buying or selling sentiment until exercised or sold.